Trials / Completed
CompletedNCT01302249
AR-12286 in Combination With Latanoprost
A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Aerie Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a double-masked, randomized, multi-center, active-controlled, crossover comparison of the addition of AR-12286 or timolol to latanoprost in the treatment of elevated intraocular pressure (IOP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Latanoprost 0.005% | q.d. |
| DRUG | AR-12286 Ophthalmic Solution 0.5% | |
| DRUG | Timolol maleate ophthalmic solution 0.5% |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2011-02-24
- Last updated
- 2014-05-08
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01302249. Inclusion in this directory is not an endorsement.